Core Viewpoint - Kintor Pharmaceutical Co., Ltd. reported significant growth in its mid-year results for 2025, leading to a stock price increase of over 3% following the announcement [1] Financial Performance - Revenue reached 50.961 million HKD, representing a year-on-year increase of 703.8% [1] - Gross profit amounted to 29.369 million HKD, showing a year-on-year growth of approximately 1,716% [1] - Net loss narrowed to 75.483 million HKD, a reduction of 78.53% compared to the previous year [1] - Earnings per share reported a loss of 0.14 HKD [1] Contributing Factors - The reduction in losses was attributed to decreased research and development expenses, lower administrative costs, an increase in net foreign exchange gains, and higher gross profit [1]
港股异动 | 科济药业-B(02171)绩后涨超3% 中期净亏损7548.3万元 同比收窄78.53%